招生導師簡介

1、招生導師簡介一、個人簡介198奔畢業(yè)于中國預防醫(yī)科院病毒學研究所獲碩士學位.研究員,博士生導師,現任病毒肝炎室主任.屢次承當國家“九五、“十五、“十一五、“十二五攻關和973、863重大專項等課題研究.擔任過中華人民共和國藥典委員會委員、中華醫(yī)學會免疫診斷專家委員會委員、國家科技部創(chuàng)新基金評審委員會委員、中國肝炎基金會理事、中國遺傳學會青年委員會委員、中華實驗和臨床病毒學雜志副主編編委、中國醫(yī)療事故鑒定委員會委員、北京市自然基金委員會評委、病毒學報編委等社會兼職.曾榮獲戊型肝炎病原學及流行病學研究的衛(wèi)生部一等獎；戊型肝炎病毒學及流行病學研究的國家級科技進步二等獎；丙型肝炎分子生物學、血清學診斷

2、方法的研究和臨床應用的衛(wèi)生部科技進步一等獎；丙型肝炎分子生物學、血清學診斷方法的研究和臨床應用的國家級科技進步二等獎；戊型肝炎病毒分子生物學、血清學及散發(fā)性戊型肝炎研究的衛(wèi)生部科技進步二等獎；丙型肝炎分子生物學、血清學診斷方法的研究和臨床應用的北京市科技進步一等獎；中華預防醫(yī)學會科學技術一等獎.先后獲得中國青年科學家獎、中央國家機關十大杰出青年稱號以及衛(wèi)生部突出奉獻中青年專家獎等.在國內外發(fā)表科學論文百余篇,對我國病毒性疾病的研究和防控工作做出了突出奉獻.在國內外本專業(yè)領域有較高的學術地位.二、主要研究方向肝炎病毒免疫及其在預防限制中的應用肝炎基因工程疫苗的實驗室研究和臨床考核評價生物工程上游

3、技術與下游技術的連接途徑新型病原實驗室應對方法和快速反響技術三、代表性科研工程國家科技支撐方案：手足口病(EV71型)疫苗的研制國家十一五重大專項：我國乙型病毒性肝炎疫苗保護效果及免疫持久性的系統(tǒng)評價北京市科委：乙肝疫苗免疫評價與新型疫苗的研發(fā)四、代表性論文、成果(2021年以來)1. GenotypingofacutehepatitisAvirusisolatesfromChina,2003-2021.2021Jul;83(7):1134-41.2. HepatitisCvirus-specificcellularandhumoralimmuneresponsesfollowingimmun

4、izationwithamulti-epitopefusionprotein.IntJMolMed,2021,29(1):12-17.Epub2021Sep283. EpidemiologicalchangesinhepatitisBprevalenceinanentirepopulationafter20yearsoftheuniversalHBVvaccinationprogramme.2021,139:1159-11654. EffectivenessofaChinesehamsterovarycellderivedhepatitisBvaccineinChineseRuralCommu

5、nities.Vaccine,2021,29:3905-39085. Long-termefficacyof10T2yearsafterbeingimmunizedwithChinesehamsterovarycellderivedhepatitisBvaccineinChineseRuralCommunities_Vaccine30(2021)205120536. Ef?cacyofyeast-derivedrecombinanthepatitisBvaccineafterbeingusedfor12yearsinhighlyendemicareasinChina.Vaccine.2021,

6、30:6623-6627.7. DevelopmentofaHepatitisDeltaVirusAntibodyAssayforStudyofthePrevalenceofHDVAmongIndividualsInfectedwithHepatitisBVirusinChina.JMedViro.2021,84:445-449.8. GeneticDiversityofHepatitisAVirusinChina:VP3-VP1-2AGenesandEvidenceofQuasispeciesDistributionintheIsolates.PlosOne,2021;8(9):e74752

7、.9. EpidemiologyofHepatitisCVirusInfectionandRiskFactorAnalysisintheHebeiProvince,China.PlosOne,2021;8(9):e75586.10. ComparativeevaluationofanovelTaqManreal-timereversetranscription-polymerasechainreactionassayforhepatitisAvirusdetection.JIntMedRes,2021;42(2):427-434.11. Constructionandimmunological

8、evaluationoftruncated119152inthemajorimmunodominantregion(MIR).BBRC,2021;439:84-89.12. EpidemiologyofHepatitisEVirusinChina:ResultsfromtheThirdNationalViralHepatitisPrevalenceSurvey,2005-2006PLOSONE2021;9(10)://10.1371/journal.pone.011083713. Multiplexhydrolysisprobereal-timePCRforsimulta

9、neousdetectionofhepatitisAvirusandhepatitisEvirus.IntJMolSci,2021,15(6):9780-9788.14. MigrationPatternsofHepatitisCVirusinChinaCharacterizedforFiveMajorSubtypesBasedonSamplesfrom411VolunteerBloodDonorsfrom17ProvincesandMunicipalities.jvi.July2021Volume88Number13p.7120-712915. Riskfactorsassociatedwi

10、thimmuneprophylaxisfailureagainstmothertochildtransmissionofhepatitisBvirusandhepatitisBvaccinationstatusinYunnanprovince,China.Vaccine.2021Jun5;32(27):3362-6.16. MolecularepidemiologicalstudyofhepatitisBvirusgenotypesinSouthwest,China.JMedVirol.2021Aug;86(8):1307-1313.17. Thelong-termefficacyofChin

11、esehamsterovarycellderivedhepatitisBvaccineafterbeingusedfor14T6yearsinChineseruralcommunities.Vaccine,2021,33:294-297.18. Thelong-termefficacy,13-23years,ofaplasma-derivedhepatitisBvaccineinhighlyendemicareasinChina.Vaccine,2021,33:2704N70919. EvolutionandgeneticcharacterizationofhepatitisAvirusiso

12、latesinChina.InternationalJournalofInfectiousDiseases.2021.33,e156七158.20. Full-lengthgenomecharacterizationandquasispeciesdistributionofhepatitisAvirusisolatesinChina.VirolRep.2021.21. ImmuneresponsestoHBsAgconjugatedtoproteinDofnon-typeablehaemophilusinfluenzainmice.Plosone202110(2):e0117736.22. JikunZhou,YongZhangandShengliBi.RiskfactorsofhepatitisCvirustransmissionandgenotypedistributioninformerblooddonorsfromChineseruralarea.BMCPublicHealth(2021)15:184.DOI10.1186/s12889-015-1535-6.23. Enh